No title
Purpose: To assess mean change in visual acuity (VA) overall and stratified by baseline VA after 1 and 2 years’ treatment with aflibercept in a real-life setting. Methods: This was an observational cohort study using nationwide data from the Swedish Macula Register. Treatment-naïve patient eyes with wet age-related macular degeneration and prescribed aflibercept from January 2013 to December 2014
